The metabolism of endothelial cells during vessel sprouting remains poorly studied. Here we report that endothelial loss of CPT1A, a rate-limiting enzyme of fatty acid oxidation (FAO), causes vascular sprouting defects due to impaired proliferation, not migration, of human and murine endothelial cells. Reduction of FAO in endothelial cells did not cause energy depletion or disturb redox homeostasis, but impaired de novo nucleotide synthesis for DNA replication. Isotope labelling studies in control endothelial cells showed that fatty acid carbons substantially replenished the Krebs cycle, and were incorporated into aspartate (a nucleotide precursor), uridine monophosphate (a precursor of pyrimidine nucleoside triphosphates) and DNA. CPT1A silencing reduced these processes and depleted endothelial cell stores of aspartate and deoxyribonucleoside triphosphates. Acetate (metabolized to acetyl-CoA, thereby substituting for the depleted FAOderived acetyl-CoA) or a nucleoside mix rescued the phenotype of CPT1A-silenced endothelial cells. Finally, CPT1 blockade inhibited pathological ocular angiogenesis in mice, suggesting a novel strategy for blocking angiogenesis.
The metabolism of endothelial cells during vessel sprouting remains poorly studied. Here we report that endothelial loss of CPT1A, a rate-limiting enzyme of fatty acid oxidation (FAO), causes vascular sprouting defects due to impaired proliferation, not migration, of human and murine endothelial cells. Reduction of FAO in endothelial cells did not cause energy depletion or disturb redox homeostasis, but impaired de novo nucleotide synthesis for DNA replication. Isotope labelling studies in control endothelial cells showed that fatty acid carbons substantially replenished the Krebs cycle, and were incorporated into aspartate (a nucleotide precursor), uridine monophosphate (a precursor of pyrimidine nucleoside triphosphates) and DNA. CPT1A silencing reduced these processes and depleted endothelial cell stores of aspartate and deoxyribonucleoside triphosphates. Acetate (metabolized to acetyl-CoA, thereby substituting for the depleted FAOderived acetyl-CoA) or a nucleoside mix rescued the phenotype of CPT1A-silenced endothelial cells. Finally, CPT1 blockade inhibited pathological ocular angiogenesis in mice, suggesting a novel strategy for blocking angiogenesis.
Angiogenesis relies on the proliferation and migration of endothelial cells 1 . The importance of endothelial cell proliferation for expansive growth of the vascular network has long been recognized 2 . While numerous molecules regulating vessel sprouting have been identified 3 , little is known about the role of metabolism. We recently reported that endothelial cells generate 85% of their ATP for vessel sprouting via glycolysis 4 . Fatty acid oxidation (FAO) has been linked in various cell types to ATP production and to ROS scavenging during cellular stress, but apart from a few earlier in vitro reports 5 , the role and importance of FAO in endothelial cells during angiogenesis in vivo is undefined.
By shuttling long-chain fatty acids into mitochondria, carnitine palmitoyltransferase 1 (CPT1) constitutes a rate-limiting step of FAO. Oxidation of palmitate generates acetyl-CoA, which fuels the TCA cycle. Apart from generating ATP, the TCA cycle also provides precursors for macromolecule synthesis, necessary for proliferation. However, fatty acids have not yet been shown to function as carbon sources for biosynthetic processes. Here we elucidated the role of FAO in endothelial cells during angiogenesis, and studied how FAO determines endothelial cell behaviour.
FAO stimulates vessel sprouting via EC proliferation
To study the role of mitochondrial FAO in vessel sprouting, we silenced CPT1A, the most abundant CPT1 isoform in human umbilical venous endothelial cells (HUVECs), which lowered levels of CPT1A mRNA and protein and reduced FAO flux (Extended Data Fig. 1a-f ). In contrast, silencing of CPT1C, expressed at lower levels (Extended Data Fig. 1a ), did not affect FAO (Extended Data Fig. 1g ). As similar data were obtained in other endothelial cell subtypes (Extended Data Fig. 1d , h), we used HUVECs (hereafter referred to as endothelial cells (ECs)) for our study.
In EC spheroids, CPT1A silencing (CPT1A knockdown (CPT1A KD )) decreased vessel sprout length and numbers (Fig. 1a-c and Extended Data Fig. 1i ). This defect was due to decreased EC proliferation, as CPT1A KD reduced proliferation and had only minimally additive effects on mitomycin-C-treated mitotically inactivated ECs (Fig. 1c-f and Extended Data Fig. 1i, j) . By contrast, CPT1A KD did not affect EC migration or motility ( Fig. 1g -i and Extended Data Fig. 1k ). Similar results were obtained when silencing long-chain acyl-CoA dehydrogenase (ACADVL), another FAO gene (Extended Data Fig. 1l-o) . Additional evidence for a role of FAO in vessel sprouting was provided by overexpression of CPT1A (CPT1A OE ), which yielded opposite results to those obtained by CPT1A KD (Extended Data Fig. 1p-t) . Thus, CPT1A-driven FAO regulates EC proliferation during vessel sprouting.
To study the effects of endothelial CPT1A deficiency on vessel formation in vivo, we used Cpt1a lox/lox mice intercrossed with VEcadherin(PAC)-Cre ERT2 mice (CPT1A DEC mice) (Extended Data Fig.  1u ). Isolectin-B4 staining of retinal vessels of transgenic pups at postnatal day (P) 5 revealed that EC loss of CPT1A diminished the number of vascular branch points, and reduced radial expansion of the vascular plexus ( Fig. 2a-e ). This was not caused by increased vessel regression ( Fig. 2f-h ) but by reduced EC proliferation ( Fig. 2i-k) . Furthermore, CPT1A DEC mice had normal numbers of filopodia ( Fig. 2l -n) and vessel maturation (Fig. 2o, p and Extended Data Fig.  1v ). Thus, impaired angiogenesis in CPT1A DEC mice was due to EC proliferation defects. 
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CPT1A KD does not cause ATP or redox imbalance
To explore by which mechanism FAO regulates EC proliferation, we studied whether CPT1A KD impaired EC proliferation by causing energy stress due to ATP depletion. However, CPT1A KD did not lower ATP levels, nor did it affect the energy charge or ADP/ATP ratio (Fig. 3a, b and Extended Data Fig. 2a ). This was not surprising, as FAO generated only 5% of the total amount of ATP in ECs 4 . Oxygen consumption (OCR) coupled to ATP synthesis was modestly reduced (Fig. 3c ), but could not explain the sprouting defect, as blocking mitochondrial ATP production with oligomycin failed to affect sprouting of control and CPT1A KD ECs, suggesting that CPT1A KD impaired sprouting independently of mitochondrial ATP production ( Fig. 3d and Extended Data Fig. 2b) . Additional experiments confirmed that CPT1A KD ECs were not in energy stress (Extended Data Fig. 2c, d ).
We also explored whether CPT1A KD impaired vessel sprouting by altering redox balance. CPT1A KD increased ROS levels by only 20%, an increase reported to enhance EC proliferation 6 , without affecting the percentage of oxidized glutathione or disturbing redox homeostasis ( Fig. 3e, f ). Furthermore, lowering ROS levels by using N-acetyl-cysteine (NAC) did not restore vessel sprouting upon CPT1A silencing ( Fig. 3g and Extended Data Fig. 2e ). Finally, CPT1A KD did not compromise EC survival and did not increase levels of oxidative DNA damage markers (Extended Data Fig. 2f -j). Thus, CPT1A KD did not impair vessel sprouting by inducing toxic ROS levels.
FAO is used for de novo synthesis of nucleotides
We thus considered a novel role for FAO in EC proliferation and explored whether FAO regulated the production of biomass building blocks. Supplementing EC monolayers with [U-13 C]palmitate or an algal [U-13 C]fatty acid mix revealed that carbons from fatty acids provided a substantial fraction of the total carbon fuelling the TCA cycle intermediates and TCA-cycle-derived amino acids; this fraction was similar to the contribution of carbons from glutamine and glycolytic carbon ( Fig. 4a -c) 7 . This was unexpected as many cancer cell types rely almost exclusively on glucose and glutamine to fuel the TCA cycle 8 . CPT1A KD also lowered the cellular pool size of citrate, aspartate and glutamate ( Fig. 4d ).
Since TCA intermediates are used for the synthesis of biomass precursors, and inhibition of FAO limited the supply of these TCA intermediates, we explored whether CPT1A KD impaired protein and/or nucleotide synthesis. CPT1A KD did not, however, impair de novo protein synthesis ( Fig. 4e ) and did not consistently alter intracellular amino acid levels ( Fig. 4d ). Also, CPT1A KD still lowered EC proliferation when protein synthesis was reduced by cycloheximide ( Fig. 4f ), suggesting that a decrease of de novo protein synthesis did not prevent CPT1A silencing to establish its proliferation defect.
Given that aspartate is a precursor of nucleotides and its levels were reduced upon CPT1A KD , we explored whether fatty-acid-derived carbons were used for de novo ribonucleotide synthesis. Label from [U-14 C]palmitate was incorporated into RNA in control ECs, and this process was decreased upon CPT1A KD (Fig. 4g ). However, despite this, CPT1A KD ECs did not have reduced RNA levels and pools of ribonucleotides (rNTPs) ( Fig. 4h , i), presumably because of compensatory production by salvage pathways. Thus, insufficient RNA synthesis did not cause the proliferation defect of CPT1A KD ECs.
We therefore assessed whether impaired de novo deoxyribonucleotide synthesis caused the proliferation defect of CPT1A KD ECs. Label from [U-14 C]palmitate was incorporated into DNA, and this was reduced upon CPT1A silencing ( Fig. 4j ). As CPT1A KD also decreased de novo DNA synthesis ( Fig. 1d ), we hypothesized that FAO blockade reduced aspartate levels and thereby compromised de novo deoxyribonucleotide biosynthesis. Indeed, labelled carbons from [U-13 C]palmitate were incorporated in the pyrimidine precursors uridine monophosphate (UMP) and uridine-59-triphosphate (UTP), and this incorporation was reduced upon CPT1A silencing (Fig. 4k , l and Extended Data Fig. 3a ). Moreover, quantification of deoxyribonucleotide (dNTP) levels confirmed that CPT1A KD lowered the intracellular levels of all pyrimidine (dCTP, dTTP) and purine deoxyribonucleotides (dATP, dGTP) needed for DNA replication (Fig. 4m ). Thus, in contrast to the retained rNTP levels, CPT1A KD depleted the pool of dNTPs.
To functionally confirm that the effect of CPT1A KD depends on reduced de novo nucleotide synthesis, we inhibited de novo synthesis of nucleotides by methotrexate (MTX) and 5-fluorouracil (5FU), which reduced vessel sprouting in control but did not further reduce vessel sprouting in CPT1A KD cells (Fig. 4n , o and Extended Data Fig. 3b , c). Thus, CPT1A KD reduced sprouting mainly via inhibition of de novo deoxyribonucleotide synthesis.
To confirm the role of fatty-acid-derived carbons for nucleotide synthesis, we supplemented CPT1A KD cells with acetate (which is converted to acetyl-CoA that can fuel the TCA cycle). Treatment of CPT1A KD ECs imbalance. a, Intracellular ATP levels in control and CPT1A KD ECs (n 5 4). b, Energy charge measurement (ratio) in control and CPT1A KD ECs (n 5 3; P 5 NS). c, ATP coupled oxygen consumption rate (OCR ATP , expressed relative to control) in control and CPT1A KD ECs (n 5 3). d, Total sprout length upon oligomycin (oligo) treatment in control and CPT1A KD EC spheroids (n 5 3). e, Intracellular ROS levels in control and CPT1A KD ECs as measured using the fluorescent ROS detection reagent chloromethyl-29,79dichlorofluorescin diacetate, acetyl ester (CM-DCF) (n 5 6). f, Oxidized glutathione levels as per cent of total glutathione, in control and CPT1A KD ECs (n 5 3; P 5 NS). g, Total sprout length upon N-acetyl-cysteine (NAC) treatment in control and CPT1A KD EC spheroids (n 5 3). Data are mean 6 s.e.m. of n independent experiments. Statistical test: mixed models (a-g). NS, not significant. *P , 0.05, ***P , 0.001, ****P , 0.0001. with acetate completely restored the levels of aspartate and dNTPs ( Fig. 5a, b ). Furthermore, CPT1A KD and control cells incorporated comparable amounts of [U-13 C]acetate into UMP and UTP ( Fig. 5c, d) . Functionally, acetate rescued the sprouting defect of CPT1A KD ECs ( Fig. 5e and Extended Data Fig. 3d -g). Also, blockade of the ATP synthase did not prevent this rescue, indicating that acetate was not used for the production of ATP but instead for the synthesis of biomass (Extended Data Fig. 3h , i).
Supplementation of a mix of nucleosides or dNTPs also fully rescued the sprouting defect of CPT1A KD vessels, indicating that FAO blockade impaired nucleotide synthesis ( Fig. 5f and Extended Data Fig. 3j , k). Notably, acetate or the nucleoside mix were unable to rescue the CPT1A KD sprouting defect upon mitotic inactivation of CPT1A KD ECs, indicating that their effect relied on stimulating EC proliferation (Extended Data Fig. 3l ; not shown). Thus, CPT1A-driven FAO is critical for de novo deoxyribonucleotide synthesis to ensure EC proliferation during sprouting.
Glucose partly compensates for FAO loss
Nucleotides can also be synthesized from glucose and glutamine 9 , so we asked whether ECs would compensate for the loss of FAO using these nutrients. CPT1A KD increased the oxidation of glucose but not of glutamine (Extended Data Fig. 3m , n), and increased glycolytic carbon incorporation into citrate and aspartate, whereas glutamine incorporation into citrate and aspartate was not (citrate), or only negligibly (aspartate), altered ( Fig. 5g and Extended Data Fig. 3o ). The relative activity of pyruvate dehydrogenase and pyruvate carboxylase was increased in CPT1A KD ECs ( Fig. 5h-j) , which can contribute to the increase in glucose oxidation. Nonetheless, this compensation was insufficient to rescue the proliferation defect of CPT1A KD ECs, indicating that fatty acids are irreplaceable for DNA replication in ECs.
Most cells do not use fatty acids for DNA synthesis
To assess the broader relevance of the role of FAO in deoxyribonucleotide synthesis, we studied [U-13 C]palmitate contribution to citrate in a panel of normal and malignant proliferating cells. Fibroblasts (and to a certain extent pericytes) but no other primary cells incorporated substantial amounts of fatty-acid-derived carbon into citrate ( Fig. 6a ). Except for breast cancer (T47D, MCF7) and lung cancer (A549) cell line (known to rely on FAO for ATP and NADPH production 10 ), fatty acids contributed minimally to citrate production ( Fig. 6a ). Notably, even when these cancer cells incorporated fatty-acid-derived carbons into citrate, they incorporated them to a much lesser extent into DNA ( Fig. 6b ), implying that fatty-acid-derived carbons entering the TCA 
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cycle were used for other purposes than deoxyribonucleotide synthesis.
In fact, only fibroblasts incorporated similar amounts of fatty-acidderived carbons into DNA to ECs ( Fig. 6b ).
Inhibition of CPT1A impairs angiogenesis
Pharmacological agents with FAO-blocking activity are being used clinically 11 . To explore whether pharmacological blockade of CPT1 reduced pathological angiogenesis, we used etomoxir, an irreversible inhibitor of mitochondrial long-chain FAO. Etomoxir reduced FAO and EC proliferation, but not migration in vitro (Extended Data Fig. 4a -c).
In vivo, etomoxir induced similar retinal vascular defects as CPT1A deficiency in ECs (Extended Data Fig. 4d -g) and reduced pathological angiogenesis in a model of retinopathy of prematurity ( Fig. 6c-e ). The mechanistic model of our findings is represented in Fig. 6f .
Discussion
The novelty of this study relates to several observations. First, FAO is critical for vessel sprouting in vivo, and the extent of its function is greater than expected based on earlier reports 5 . Second, FAO affects proliferation, not migration, of ECs, which caused vessel sprouting defects. Unlike PFKFB3-driven glycolysis, which affects EC proliferation and migration 4 , FAO selectively regulates EC proliferation, indicating that distinct metabolic pathways control distinct EC functions during vessel sprouting. Third, we discovered an unknown role of fatty-acidderived carbons in de novo nucleotide synthesis for DNA replication in ECs. Our results indicate that FAO promotes de novo deoxyribonucleotide synthesis by providing carbons for the production of aspartate and glutamate. The fact that aspartate is a direct carbon donor for the synthesis of the pyrimidine nucleobase (Extended Data Fig. 3a ) and that the pool of aspartate was reduced in CPT1A KD ECs explains why pyrimidine dNTP levels were reduced. But aspartate and glutamate also serve as a nitrogen source for the production of the nucleobase of pyrimidines and purines. This explains why the synthesis of purine dNTPs was also impaired upon FAO blockade. Interestingly, of other primary and malignant cell types tested, only ECs and fibroblasts used substantial amounts of fatty acid carbons for DNA synthesis, even though certain cancer cell lines incorporated fatty-acid-derived carbons in the TCA cycle. Fatty acids were irreplaceable for DNA synthesis, but not for protein and RNA synthesis. A possibility is that CPT1A KD ECs maintained RNA levels by producing rNTPs via nucleotide salvage. Indeed, quiescent/ hypo-proliferative cell types (CPT1A KD ECs are hypo-proliferative) rely primarily on nucleotide salvage rather than on de novo nucleotide synthesis to synthesize RNA 12 . By contrast, proliferating cells switch on de novo synthesis of dNTPs to duplicate their DNA genome 13 . Support for the notion that ECs use nucleotide salvage primarily for RNA synthesis is provided by evidence that incorporation of carbons from hypoxanthine (a nucleotide salvage intermediate) was higher in RNA than DNA (Extended Data Fig. 3p ). This may explain why FAO blockade affected dNTPs levels but not rNTP levels. A recent study on the role of pyruvate kinase isoenzymes documented that PKM1 expression reduced incorporation of 13 C label from [U- 13 C]glucose and [U-13 C]glutamine in UMP and decreased dNTP levels and cell proliferation, yet did not alter rNTP levels 14 , illustrating that the production of rNTPs and dNTPs is regulated differently.
Fourth, we identified that fatty-acid-derived carbons entering the TCA cycle are used for biomass production. This was unexpected since evidence in rapidly proliferating cancer cells indicated that glucose and glutamine are used as the primary carbon source for de novo deoxyribonucleotide synthesis 8, 14 . The utilization of fatty acids for biomass production is, however, not unprofitable. Indeed, given that fatty acids are a much richer carbon source than glucose or glutamine, use of fatty acids is an efficient mechanism to generate nucleotides. Finally, pharmacological CPT1 blockade reduced pathological angiogenesis, which 13 C]palmitate to citrate in various primary cells and cancer cell lines, expressed relative to the value in ECs (n 5 9 for ECs, n 5 8 for pericytes (Per), n 5 6 for T cells, B16, A549 and 143B, n 5 5 for Panco2, n 5 4 for DU145, T47D and MDA, n 5 3 for fibroblasts (Fib), ES cells, HCT, CT2A, U87 and MCF7). b, Contribution of [U-14 C]palmitate to DNA, expressed relative to the value in ECs (n 5 14 for ECs, n 5 6 for pericytes (Per), n 5 5 for B16, Panco2 and A549, n 5 4 for fibroblasts (Fib), T47D, 143B and T cells, n 5 3 for HCT, MDA, DU145, U87, CT2A, MCF7 and ES cells). c, d, Representative images (original magnification, 103) of retinal flat-mounts of retinopathy of prematurity (ROP) mice treated with vehicle (c) or etomoxir (Eto) (d). e, Vascular tuft area in control and etomoxir-treated pups (n 5 13 for WT and 9 for etomoxir). f, Mechanistic model. Top, control ECs: uptake of palmitate and FAO in ECs are not essential for the production of ATP and NADPH (indicated in the shaded box), but fatty-acidderived carbons are incorporated in amino acids, and in precursors of rNTPs and dNTPs; how critically these pathways regulate EC proliferation cannot be assessed in control cells (denoted by question mark). Bottom, CPT1A KD ECs: silencing of CPT1A reveals, however, that decreasing FAO depletes dNTP pools, without affecting rNTP and protein synthesis, implying that fatty acids are irreplaceable for DNA synthesis; since de novo synthesis of dNTPs is critical for DNA replication, CPT1A silencing impairs EC proliferation. Data are mean 6 s.e.m. of n independent experiments (a, b) or the total number of mice (of 4 litters) (e). Statistical test: two-sided t-test (a, b); mixed models (e). NS, not significant. *P , 0.05, **P , 0.01, ***P , 0.001, ****P , 0.0001.
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G2015 Macmillan Publishers Limited. All rights reserved METHODS Chemicals and reagents. Collagen type 1 (rat tail) was from Millipore or from PureCol (bovine) (Advanced Biomatrix, USA). The CPT1A inhibitor (1)-etomoxir sodium salt hydrate was purchased from CNIO Carlos III Therapies. Mitomycin C (MitoC), sodium palmitate, dimethyl sulfoxide (DMSO), N-acetyl-cysteine (NAC), sodium acetate, oligomycin, cycloheximide, cytidine, adenine, guanosine, methotrexate, carnitine, dNTP mix and tamoxifen were from Sigma-Aldrich (Bornem, Belgium). 5-fluorouracil (TEVA Pharma Belgium) was obtained from the pharmacy of the university hospital Leuven. Nucleoside mix was from Millipore (Belgium) 15 . Hoechst 33342 and L-homopropargylglycine (HPG) were from Molecular Probes and L-glutamine and penicillin/streptomycin were from Gibco (Invitrogen, Life Technologies, Ghent, Belgium). Uniformly labelled [U- 13 Cell culture. Primary cells: human umbilical vein endothelial cells (HUVECs) were freshly isolated from different donors as described 16 (with approval of medical ethical committee KU Leuven/UZ Leuven and informed consent obtained from all subjects), regularly tested for mycoplasma and used between passage 1 and 5. HUVECs were cultured in M199 medium (1 mg ml 21 D-glucose) from Gibco (Invitrogen, Life Technologies, Ghent, Belgium) supplemented with 20% fetal bovine serum (FBS) Biochrom GmbH (Germany), 2 mM L-glutamine, 30 mg l 21 endothelial cell growth factor supplements (EGCS), 10 units ml 21 heparin (Sigma), 100 IU ml 21 penicillin and 100 mg ml 21 streptomycin or in endothelial basal medium (EBM-2) supplemented with endothelial growth medium SingleQuots (Promocell, Germany). In all experiments, HUVECs were always used as singledonor cultures. Human aortic ECs (HAECs) and adult human dermal blood microvascular ECs (HMVEC-dBlAd) were either from Clonetics, Lonza (Braine-l'Alleud, Belgium) or isolated from umbilical cords for arterial ECs or from placenta for microvascular ECs, and were cultured in the recommended medium supplemented with SingleQuots (EGM-2 or EGM-2 MV; Clonetics, Lonza, Braine-l'Alleud, Belgium). Human pericytes were isolated from human placenta using gentleMACS tissue dissociator (Miltenyi Biotec) and incubation with collagenase 0.2% (GIBCO) and DNase 80 U ml 21 (Life technologies) for 30 min at 37 uC followed by Percoll gradient 5 (GE Healthcare) centrifugation, or from human adipose tissue using collagenase 0.2% in 0.9% NaCl and 2 mM CaCl 2 for 1 h at 37 uC. Thereafter, the cell suspension was immunomagnetically sorted by using CD31 and CD146 antibodies conjugated with microbeads (Miltenyi Biotec). CD146 1 CD31 2 sorted cells were seeded in aMEM plus 10% FBS and 5 nM platelet derived growth factor-BB (PDGF-BB). Human T cells: peripheral blood mononuclear cells (PBMCs) were isolated from whole blood by Ficoll-Paque Plus (Amersham Biosciences) density gradient centrifugation. PBMCs were collected, washed with cold PBS and subsequently used for naive T-cell isolation. Naive T-cells were isolated with a pan T-cell isolation kit (MACS Myltenyi Biotec). After isolation, naive T cells were seeded in plates coated with anti-CD3 antibody (5 mg ml 21 ), and anti-CD28 (0.5 mg ml 21 ) and IL-2 (10 ng ml 21 ) were added to the medium. All cell preparations were used in experiments as single donor cultures. Murine fibroblasts were freshly isolated from lungs of FVB mice and cultured and used between passage 1 and 5. Briefly, dissected lungs were chopped and digested in a solution of 2 mg ml 21 collagenase (Sigma blend L, Sigma-Aldrich) in RPMI media from Gibco (Invitrogen, Life Technologies, Ghent, Belgium) containing 2.5% fetal bovine serum (FBS), 10 mM HEPES, 2 mM glutamine, 100 IU ml 21 penicillin and 100 mg ml 21 streptomycin (5 ml per lung) for 1 h at 37 uC. Organoids were pelleted at 1,100 r.p.m., washed four times with digestion solution and then plated into standard tissue culture flasks in DMEM/F12 medium from Gibco (Invitrogen, Life Technologies, Ghent, Belgium) containing 5% fetal bovine serum (FBS), 2 mM glutamine, 100 IU ml 21 penicillin and 100 mg ml 21 streptomycin. The day after isolation, the medium was refreshed. Cells were then routinely maintained in 5% CO 2 and 95% air at 37 uC and the medium was replaced every second day. ES cells: G4 ES cells were routinely passaged every 2-3 days onto freshly prepared Mitomycin-C-arrested feeder layers, and were re-fed daily with fresh ES cell culture medium consisting of 500 ml Knockout DMEM medium (Life Technologies) supplemented with 2 mM L-glutamine (Life Technologies), 90 ml fetal bovine serum (Biochrom BmgH), MEM nonessential amino acids 1003 (GIBCO/Invitrogen), 0.01 mM b-mercaptoethanol (Sigma-Aldrich), 1 mM sodium pyruvate (GIBCO/Invitrogen), penicillin/streptomycin 1003 (Life Technologies), and 2,000 U ml 21 leukaemia inhibitory factor (Merck Millipore). Prior to testing whether ES cells use fatty acids for DNA synthesis they were replated at least 3 times on gelatinized dishes without any feeders. Doing so, all feeder cells were selectively removed from the cultures, resulting in 100% pure undifferentiated ES cell cultures. Tumour cell lines: murine melanoma B16 clone F10.9 (obtained from American Type Culture Collection, ATCC; LGC Standards, Molsheim Cedex, France) and Panco2 murine pancreatic carcinoma cells (provided by B. Wiedenmann, Charite¨, Berlin, Germany) were cultured in RPMI containing 10% FBS. MCF7 (human breast cancer), HCT116 (human colon carcinoma), MDA-MB-468 (human breast carcinoma cells), T47D (human ductal breast epithelial tumour cells), DU145 (human prostate cancer cells), 143B (human osteosarcoma cells) and A549 (human lung carcinoma cells) were cultured in DMEM containing 10% FBS, 2 mM glutamine, 100 IU ml 21 penicillin and 100 mg ml 21 streptomycin. CT2A murine glioblastoma cells and U87 human glioblastoma cells were cultured in DMEM containing 10% FBS and 2 mM glutamine (Invitrogen, Life Technologies, Ghent, Belgium) supplemented with conditioned medium obtained from CT2A or U87 cells. Knock-down and overexpression strategies. RNA interference: CPT1A silencing was achieved using a validated pool of siRNA duplexes directed against human CPT1A (Trifekta Kit, IDT) and lipofectamine RNAi Max transfection reagent (Invitrogen, Belgium) according to the manufacturer's instructions. A scrambled siRNA was used as negative control. Lentiviral transductions: for overexpression of murine CPT1A, the cDNA was cloned in the pRRLsinPPT. CMV.MCS MM W prevector 17 . Of note, this increased FAO in some but not all EC isolations, suggesting that in such cases CPT1A abundance was not limiting the maximal capacity of FAO. However, whenever FAO was enhanced, sprout numbers and length of EC spheroids were increased. To generate shRNA vectors against CPT1A, CPT1C, or ACADVL, oligonucleotides were cloned into the pLKO-shRNA2 vector (No. PT4052-5; Clontech, Westburg BV, Leusden, The Netherlands) (for RNA sequences, see below). A nonsense scrambled shRNA sequence was used as a negative control. Production of lentiviruses by transfection into 293T cells was performed as described 18 . For transductions, a multiplicity of infection (MOI) of 20 was used in all shCPT1A experiments. For transductions with shACADVL and shCPT1C and for fluorescent ubiquitination-based cell cycle indicator (FUCCI; see below) and CPT1A overexpression, a MOI of 10 was used. Cells were transduced overnight and re-fed with fresh medium the next day. Transduced cells were used in functional assays at least 3 to 4 days after transduction. Of note, similar data were obtained using siRNA and two non-overlapping shRNAs directed against CPT1A. In vitro assays. Proliferation was quantified by incubating cells for 2-24 h with 1 mCi ml 21 [ 3 H]thymidine. Thereafter, cells were fixed with 100% ethanol for 15 min at 4 uC, precipitated with 10% trichloroacetic acid and lysed with 0.1 N NaOH. The amount of [ 3 H]thymidine incorporated into DNA was measured by scintillation counting. Scratch wound migration assay: a scratch wound was applied on confluent EC monolayers (pretreated with MitoC where indicated) using a 200 ml tip, 24 h after seeding (100,000 cells per well in 24-well plates). After scratch wounding and photography (T 0 ), the cultures were further incubated in fully supplemented EBM2 medium for 6-8 h (until near closure was reached in the control condition), and photographed again (T x ). Migration distance (gap area at T 0 minus gap area at T x ) was measured with NIH Image J software package and is expressed in arbitrary units. Modified Boyden chamber migration assays were performed using MitoC-treated (24 h treatment with 2 mg ml 21 MitoC) ECs. Therefore, 50,000 cells were seeded in fully supplemented EBM2 medium on 0.1% gelatinecoated transwells. Upon adherence, the transwells were washed and re-fed with medium containing only 0.1% FBS and transferred to bottom wells containing medium with 0.1% FBS (baseline) or 5% FBS (migration stimulus). Transwells were incubated for 16 h and processed and analysed for migrated cells as described 19 . Lamellipodia formation assay: the number and area of lamellipodia were measured on still photos of time-lapse recordings of sparsely seeded ECs, using the Axiovision morphometric analysis software (Carl Zeiss, Munich, Germany) with in-house developed macros. Lamellipodia area is expressed in per cent of total cell area. Directionality of migration was assessed by analysis of the total length of the migration track of a cell. The directionality value was then calculated by dividing the distance between the start and end location of the cell by the total track length; a higher directionality value denotes higher migration directionality. Experiments were performed with or without genetic shRNA CPT1A silencing. Spheroid capillary sprouting assay: ECs were incubated overnight in hanging drops in EGM-2 medium containing methylcellulose (20 volume% of a 1.2% solution of methylcellulose 4000 cP) (Sigma-Aldrich, Bornem, Belgium) to form spheroids. For mitotic inactivation, MitoC (2 mg ml 21 ) was added to this medium. Spheroids were then embedded in collagen gel as described 20 and cultured for 20 h to induce sprouting. Compounds were added at the following concentrations during the collagen gel culture step, using corresponding vehicle concentrations as control: 20 mM sodium acetate, 53 nucleoside mix, 10 mM NAC, 1.2 mM oligomycin, 20 mg ml 21 cycloheximide, 50 mg ml 21 5FU or 20 mM MTX. Cultures were fixed with 4% PFA at room temperature and imaged under bright field using a Motic AE 31 microscope (Motic Electric Group Co Ltd, Xiamen, China) or Leica DMI6000 microscope (Leica Microsystems, Mannheim, Germany). Analysis of the number of sprouts per spheroid and the total sprout length (cumulative length of primary sprouts and branches RESEARCH ARTICLE per spheroid) was done on phase contrast images using the NIH Image J software package. To assess the number of viable versus dead cells, unfixed spheroids were stained with 500 ml of 1/500 dilution of TO-PRO3 (Invitrogen, Life Technologies, Ghent, Belgium) solution at 37 uC for 10 min, washed with PBS and imaged by confocal microscopy Zeiss LSM 510 Meta NLO or Zeiss LSM 780 confocal microscope (objectives: 310 with NA 0.3, 320 with NA 0.4) (Carl Zeiss, Munich, Germany) 21 . ATP measurement: analysis of total ATP levels was performed using a commercially available kit (ATPlite, PerkinElmer). Apoptosis: analysis of apoptosis was done by fluorescent staining for cleaved caspase 3 (Cell Signaling Technology, Bioke¨, Leiden, The Netherlands) in PFA-fixed monolayers. RNA analysis. RNA expression analysis was performed by Taqman quantitative RT-PCR as described 22 using in-house-designed primers and probes or pre-made primer sets (Applied Biosystems, Carlsbad, CA and IDT, Belgium). Sequences or pre-made primer set ID numbers are available upon request. For comparison of gene expression between conditions, expression (normalized to HPRT endogenous control) is expressed relative to control condition. For comparison between different genes, absolute expression levels were determined based on respective cDNA standard curves, and levels are expressed as copies mRNA per 10 3 copies HPRT mRNA. Immunoblot analysis. Protein extraction and immunoblot analysis were performed using a modified Laemmli sample buffer (125 mM Tris-HCl, pH 6.8 buffer containing 2% SDS and 10% glycerol) 22 or cell lysis buffer (Cell Signaling Technology) in the presence of protease and phosphatase inhibitors (Roche, Vilvoorde, Belgium). Lysates were separated by SDS-PAGE under reducing conditions, transferred to a nitrocellulose or PVDF membrane, and analysed by immunoblotting. Primary antibodies used were rabbit anti-CPT1A (No. 12252), rabbit anti-lamin A/C (No. 2032), rabbit anti-b-actin (No. 4970), anti-total AMPKa (No. 2532), rabbit antiphospho-AMPKa Thr 172 (No. 2531), anti-p21 (No. 2947), anti-phospho-ATM (No. 5883), anti-total ATM (No. 2873) (Cell Signaling Technology, Bioke¨, Leiden, The Netherlands), and anti-total p53 (FL 393, Santa Cruz Biotechnology, The Netherlands). Autophagy was analysed via western blot determination of LC3 II/I ratio (No. 3868, Cell Signaling Technology) to reveal the on-state of autophagy (autophagic flux). Equal loading was verified by Ponceau Red staining and lamin A/C or b-actin as loading controls. Appropriate secondary antibodies were from Dako (Enschede, The Netherlands). Signal was detected using the ECL system (Amersham Biosciences, GE Healthcare, Diegem, Belgium) according to the manufacturer's instructions. Densitometric quantifications of bands were done with NIH Image J software. Flow cytometry. Protein/RNA synthesis: protein synthesis was determined by incubation of cells with a methionine analogue (HPG, Invitrogen) for 24 h in full medium. RNA synthesis was determined by incubation of cells with a uridine analogue (59-ethynyl uridine, EU, molecular probes). Cells were trypsinized, PFA fixed and incorporated HPG or 59-ethynyl uridine was detected by a Click-IT reaction with Alexa fluor 647 according to the manufacturer's instructions. Alexa fluor 647 was excited with a 604-nm red laser and emission was recorded at 660 nm using a BD FACS Canto flow cytometer (Becton Dickinson Benelux NV, Erembodegem, Belgium). Intracellular ROS analysis: intracellular ROS levels were measured using the CM-DCF dye according to the manufacturer's instructions (Invitrogen, Belgium). For flow cytometry analysis the BD FACS Verse flow cytometer was used. For assessment of cell number, cells were seeded in a 24-well plate and trypsinized after 48 h growth. Cells were re-suspended in 150 ml of PBS and 100 ml of cell suspension was counted at a flow rate of 1 ml per second. Data were analysed using FlowJo analysis software. Metabolism assays. Fatty acid oxidation: ECs were incubated in fully supplemented EBM2 medium with 100 mM unlabelled palmitate and 50 mM carnitine. Cells were incubated for 2 h in growth medium containing 2 mCi ml 21 [9,10-3 H]palmitate 23, 24 . Thereafter, supernatant was transferred into glass vials sealed with rubber stoppers. 3 H 2 O was captured in hanging wells containing a Whatman paper soaked with H 2 O over a period of 48 h at 37 uC to reach saturation 25 . Radioactivity was determined by liquid scintillation counting. Glycolysis was measured analogously to fatty acid oxidation (cf supra) using 80 mCi mmol 21 [5-3 H]-D-glucose (Perkin Elmer) 23 . 14 C-glucose oxidation: cells were incubated for 6 h in growth medium containing 100 mCi mmol 21 [6-14 C]-D-glucose. Thereafter, 250 ml of 2 M perchloric acid was added to each well to stop cellular metabolism and wells were immediately covered with a 13 hyamine hydroxide-saturated Whatman paper. Overnight absorption of 14 CO 2 released during oxidation of glucose into the paper was performed at room temperature, and radioactivity in the paper was determined by liquid scintillation counting. 14 C-glutamine oxidation was performed similarly as glucose oxidation, except that we used 0.5 mCi ml 21 [U-14 C]glutamine as tracer. Palmitate or hypoxanthine mediated RNA and DNA synthesis was measured by the incorporation of 14 C into RNA or DNA using 100 mCi mmol 21 [U-14 C]palmitate or [8-14 C] hypoxanthine and was corrected for the total amount of RNA or DNA per sample. Total RNA and DNA were isolated using commercially available column-based DNA and RNA extraction kits (Qiagen) or using Trizol as an alternative extraction method for RNA or DNA. ATP coupled oxygen consumption: cells were seeded at 40,000 cells per well on Seahorse XF24 tissue culture plates (Seahorse Bioscience Europe, Copenhagen, Denmark). The measurement of oxygen consumption was performed at 10 min intervals (2 min mixing, 2 min recovery, 6 min measuring) for 3 h using the Seahorse XF24 analyser. For ATP-coupled oxygen consumption, measurements were performed before and after oligomycin (1.2 mM) treatment. Energy balance assessment: 1.5 3 10 6 cells were harvested in ice cold 0.4 M perchloric acid supplemented with 0.5 mM EDTA. pH was adjusted by adding 100 ml of 2 M K 2 CO 3 . 100 ml of the mixture was injected onto an Agilent 1260 HPLC equipped with a C18-Symmetry column (150 3 4.6 mm; 5 mm) (Waters), thermostated at 22.5 uC. Flow rate was kept constant at 1 ml min 21 . A linear gradient using solvent A (50 mM NaH 2 PO 4 , 4 mM tetrabutylammonium, adjusted to pH 5.0 using H 2 SO 4 ) and solvent B (50 mM NaH 2 PO 4 , 4 mM tetrabutylammonium, 30% CH 3 CN, adjusted to pH 5.0 using H 2 SO 4 ) was accomplished as follows: 95% A for 2 min, from 2 to 25 min linear increase to 100% B, from 25 to 27 min isocratic at 100% B, from 27 to 29 min linear gradient to 95% A and finally from 29 to 35 min at 95% A. Detection of ATP, ADP and AMP occurred at 259 nm. GSSG/GSH ratio measurement: samples were collected in 300 ml 5% TCA (trichloro-acetic acid, Sigma). 50 ml was loaded onto an Ultimate 3000 UPLC (Thermo Scientific, Bremen, Germany) equipped with a Acquity UPLC HSS T3 column (catalogue no. 186003976; 2.1 3 5 mm; 1.8 mm particles; Waters) in line connected to a Q Exactive mass spectrometer (Thermo Fisher Scientific). A linear gradient was carried out using solvent A (0.05% formic acid) and solvent B (60% methanol, 0.05% formic acid). Practically, samples were loaded at 99% solvent A and from 10 to 12 min a ramp to 100% solvent B was carried out. From 15 to 16 min the column returned to 99% solvent A and the run was stopped at 21 min. Elution of GSH and GSSG occurred at 3 and 5.5 min, respectively (isocratic separation). Flow rate was constant at 250 ml min 21 and the column temperature was kept constant at 37 uC. The mass spectrometer operated in targeted SIM mode following the ions m/z 311.11456 and 308.59499 (GSH and GSSG, respectively) using the ion 445.12003 as lock mass. The mass spectrometer ran in positive polarity, the source voltage was 3.0 kV, and the capillary temperature was set at 350 uC. Additional sheath gas flow was put at 35 and auxiliary gas flow rate at 10. Auxiliary gas heater temperature was put at 60 uC. AGC target was put at 100,000 ions with a maximum ion injection time of 200 ms, acquired at a resolution of 70,000. For the data analyses we manually integrated the peaks representing GSH and GSSG using the Thermo XCalibur Qual Browser software (Thermo Scientific) and data are represented as area of the respective GSH and GSSG peaks. Determination of 13 C-palmitate, glucose and glutamine incorporation in metabolites and total metabolite levels: for 13 C-carbon incorporation from palmitate in metabolites, cells were incubated for 48 h with labelled substrates (confirmation of steady state at that time was confirmed, see Extended Data Fig. 5 ). For ECs, [U-13 C]palmitate labelling was done in two ways: (1) '100% labelling', whereby all cold palmitate in M199 culture medium (120 mM) was replaced by 120 mM [U-13 C]palmitate using M199 medium, containing charcoal stripped serum (which does not contain any fatty acids); and (2) '50/50% labelling', whereby 100 mM [U- 13 C] palmitate was added to the EGM2 culture medium containing 100 mM cold palmitate. Both types of labelling yielded similar data and were thus pooled. For comparison with cancer cells, only the 100% labelling strategy was used. Similar labelling methods were used for glucose (5.5 mM) and glutamine (2 mM). Labelling with the algal [U-13 C]fatty acid mix was performed by using 100% labelling; this fatty acid mix contained 50 mM palmitate. Metabolites for the subsequent mass spectrometry analysis were prepared by quenching the cells in liquid nitrogen followed by a cold two-phase methanol-water-chloroform extraction 7, 26 . Phase separation was achieved by centrifugation at 4 uC and the methanolwater phase containing polar metabolites was separated and dried using a vacuum concentrator 24 . The dried metabolite samples were stored at 280 uC (refs 7, 26) . Polar metabolites were derivatized for 90 min at 37 uC with 7.5 ml of 20 mg ml 21 methoxyamine in pyridine and subsequently for 60 min at 60 uC with 15 ml of N-(tert-butyldimethylsilyl)-N-methyl-trifluoroacetamide, with 1% tert-butyldimethylchlorosilane 7, 26 . Isotopomer distributions and metabolite levels were measured with a 7890A GC system (Agilent Technologies) combined with a 5975C Inert MS system (Agilent Technologies). One microlitre of sample was injected onto a DB35MS column in splitless mode using an inlet temperature of 270 uC (refs 7, 26) . The carrier gas was helium with a flow rate of 1 ml min 21 . Upon injection, the GC oven was held at 100 uC for 3 min and then ramped to 300 uC with a gradient of 2.5 uC min 21 . The MS system was operated under electron impact ionization at 70 eV and a mass range of 100-650 amu (atomic mass units) was scanned. Isotopomer distributions were extracted from the raw ion chromatograms using a custom Matlab M-file, which applies consistent integration bounds and baseline correction to each ion 27 . In addition, we corrected for naturally occurring isotopes using the method of Fernandez et al. 28 . For relative metabolite levels, the total ion count was normalized to the internal standards norvaline and glutarate and to the protein ARTICLE RESEARCH content 7, 26 . To correct for enrichment dilution, we used previously reported methods 7, 29 ; that is, we divided the fractional contribution of a labelled metabolite of interest by the fractional contribution of its precursor (calculated by the formula below).
The total contribution of carbon was calculated using the following equation 7, 29 :
where n is the number of C atoms in the metabolite, i represents the different mass isotopomers and m refers to the abundance of a certain mass. Glycolytic carbon contribution was calculated based on [U- 13 . Samples were spun for 5 min and supernatants were dried down and were then reconstituted in 50 ml of HPLC-grade water, vortexed, centrifuged, and transferred into HPLC vials. LC-MS/MS analysis was done on a Waters Xevo TQ-S mass spectrometry was coupled to an H-Class UPLC system. Metabolites were separated by polarity using a Supelco Ascentis Express C18 column (2.7 mm particle size, 5 cm 3 2.1 mm). LC parameters are as follows: autosampler temperature, 5 uC; injection volume, 5 ml; column temperature, 50 uC; flow rate over 11 min: t 5 0, 0.4 ml min 21 ; t 5 2, 0.3 ml min 21 ; t 5 3, 0.25 ml min 21 ; t 5 5, 0.15 ml min 21 ; t 5 9, 0.4 ml min 21 ; t 5 11, 0.4 ml min 21 . The LC solvents were solvent A: 10 mM tributylamine and 15 mM acetic acid in 97:3 water:methanol (pH 4.95); and solvent B: methanol. Elution from the column was performed over 11 min with the following gradient: t 5 0, 0% B; t 5 1, 0% B; t 5 2, 20% B; t 5 3, 20% B; t 5 5, 55% B; t 5 8, 95% B; t 5 8.5, 95% B, t 5 9, 0% B; t 5 11, 0% B. Mass spectra were acquired using negative-mode electrospray ionization operating in multiple reaction monitoring (MRM) mode. The capillary voltage was 3,000 V, and cone voltage was 50 V. Nitrogen was used as cone gas and desolvation gas, with flow rates of 150 l h 21 and 600 l h 21 , respectively. The source temperature was 150 uC, and desolvation temperature was 500 uC. Argon was used as collision gas at a manifold pressure of 4.3 3 10 23 mbar. Collision energies and source cone potentials were optimized for each transition using Waters QuanOptimize software. Data were acquired and analysed using MassLynx 4.1 and QuanLynx software. Isotope labelling data was corrected for the natural abundance of different isotopes using IsoCor 32 . Determination of rNTP levels by LC-MS: rNTP was extracted with the same method as described for UTP and UMP. Additionally, 13 C-internal standards (generated based on fully labelled yeast extracts 33 ) were spiked into the extraction solution. rNTP concentrations were determined with the same LC-MS method as described for UTP and UMP. All samples were normalized to the 13 Fig. 1u ). CPT1A DEC mice were always compared with tamoxifen-treated Cre 2 Cpt1a lox/lox littermates (denoted as WT). Analysis of postnatal retinal angiogenesis: genetic endothelial-cell-specific inactivation of CPT1A in neonatal mice was achieved by intraperitoneal injection of 100 mg kg 21 tamoxifen solution (Sigma T5648; dissolved in 1:10 EtOH:corn oil) once daily from postnatal day (P) 1 to P4 in CPT1A DEC mice. Pharmacological blockade of FAO in neonatal C57BL/6 WT mice (animal facility KU Leuven) was achieved by treatment with 30-35 mg kg 21 etomoxir from P2 to P4. For detection of cell proliferation, EdU (Invitrogen) was injected 2 h before dissection. At P5, pups were killed and eyes were enucleated, fixed with 4% PFA for 2 h at 4 uC and prepared for vascular analysis. As all animal treatments were done in baseline conditions, no randomization was required. Retinal whole mounts were prepared for vascular analysis as described 4 . Only litters for which the WT littermates (for CPT1A DEC mice) or vehicle-treated littermates (for etomoxir treated mice) reached normal outgrowth and body weight at P5 were included for analysis. Radial vascular area, branching points, and number of filopodia were analysed on isolectin GS-IB4 stained retinas (see below) using the NIH Image J software package and Leica LASAF-MMAF morphometric analysis software (MetaMorph) (Leica Microsystems, Mannheim, Germany) with in-house developed macros. No statistical method was used to predetermine the sample size. Oxygen-induced retinopathy: oxygen-induced retinopathy (ROP) was induced by exposing C57BL/6 pups with their mother to 70% oxygen from P7 to P12 (ref. 35) . Pups were then returned to normoxia and injected daily with 30 mg kg 21 etomoxir or vehicle. At P17, pups were killed and eyes were enucleated, fixed in 4% PFA and retinal flat-mounts were stained for isolectin B4, using previously published methods 4 . Mosaic images were captured using the inverted Leica DMI6000B epifluorescence microscope (Leica, Manheim, Germany) and analysis of the vascular tuft area was performed using NIH Image J software. For all mouse experiments, data analysis was done by experimenters blinded to the group allocation. All experimental animal procedures were approved by the Institutional Animal Care and Research Advisory Committee of the University of Leuven. Immunohistochemistry. PFA-fixed cell cultures (4% PFA except for CPT1A staining where 2% PFA was used), spheroids (4% PFA) or whole-mount retinas (4% PFA) were subjected to immunofluorescence staining using the following isolectin conjugates or primary antibodies: isolectin GS-IB4-Alexa 488, isolectin GS-IB4-Alexa 568, isolectin GS-IB4-Alexa 647 (Molecular Probes), anti-CPT1A (Cell Signaling), anti-NG2 chondroitin sulfate proteoglycan (Chemicon), anti-Tomm20 (Abcam) and anti-collagen IV (Southern Biotech). Alexa-488, -568 or -633 conjugated secondary antibodies were used (Molecular Probes). EdU, EU and HPG staining was performed using a Click-IT assay with Alexa fluor 555 according to manufacturer's instructions.
Statistics. Data represent mean 6 s.e.m. of pooled experiments unless otherwise stated. n values represent the number of independent experiments performed or the number of individual mice phenotyped. For each independent in vitro experiment, at least three technical replicates were used, except for the [U-13 C]palmitate incorporation analysis in cell lines (at least two technical replicates) ( Fig. 6a ). Statistical significance between groups was calculated using mixed model statistics (this test does not assume normality or equal variance) with experiment as random factor to correct for variation between umbilical donors (ECs were isolated from human umbilical cords) or mouse litters. SAS statistical software version 9.3 was used for statistical analysis. For comparison of ECs with other cell types, a onesample t-test was used. Sample size for each experiment was not pre-determined. A P value ,0.05 was considered statistically significant. RNA sequences. shCPT1 RNA sequence 1, GCCATGAAGCTCTTAGACAAA; shCPT1 RNA sequence 2, CGATGTTACGACAGGTGGTTT; shACADVL RNA sequence, GCAGACATCTTCACGGTCTTT; siCPT1A RNA sequence (from IDT trifecta), AGCUCUUAGACAAAUC/AGAGAGAUAGAUUUGU.
We thank our colleagues from the metabolism community (Emile Van Schaftingen and Guido Bommer, University of Louvain, Belgium, and Frans Schuit, University of Leuven, Belgium), who alerted us to a possible confusion arising from our Article. In particular, the statement in the abstract that "Isotope labelling studies in control endothelial cells showed that fatty acid carbons substantially replenished the Krebs cycle" and similar phrases later in the text could be misunderstood as implying anaplerosis. By no means did we intend to suggest that the Krebs cycle is replenished by the net contribution of fatty acid carbons in the traditional sense of anaplerosis. Indeed, even though labelled acetyl-CoA from fatty acids enters the Krebs cycle and labels oxaloacetate, we did not want to imply net formation of oxaloacetate from acetyl-CoA, derived from fatty acids. Rather, our data suggest that under conditions of adequate availability of anaplerotic substrates (glucose, glutamine), fatty acid oxidation is important to produce sufficient amounts of dNTPs. Fatty acids provide acetyl-CoA, which helps to sustain the TCA cycle and dNTP synthesis for proliferation in conjunction with an anaplerotic substrate. Why the anaplerotic nutrients glucose and glutamine do not sustain sufficient aspartate and nucleotide synthesis in the CPT1A-silenced endothelial cells is an intriguing but outstanding question.
